MRI biomarkers for pancreatic ductal adenocarcinoma
Navid Farr1, Paolo Provenzano2, Joshua Park3, Sunil Hingorani2, and Donghoon Lee3
1Department of Bioengineering, University of Washington, Seattle, WA, United States, 2Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 3Department of Radiology, University of Washington, Seattle, WA, United States
Pancreatic cancer is a devastating disease with poor
prognosis. Pancreatic tumor therapy has been ineffective in part because
pancreatic tumors have a dense stroma inhibiting penetration of
chemotherapeutic drugs into the tumor. We performed multi-parametric MRI at
high resolution to noninvasively assess tumor progression and responses to
effective treatment. We used T1 and T2 relaxation, diffusion, magnetization
transfer effects along with 3 dimensional volume measurements to characterize
the tumors. MR measurements were then compared with histopathological results.
This abstract and the presentation materials are available to members only;
a login is required.
